Eosinophilic Airway Inflammation and Mepolizumab

Completed 38 enrolled University of Wisconsin, Madison

NaSingle-groupOpen-labelBasic science

Summary

A drug (mepolizumab) that reduces allergic inflammation will affect the function of allergy cells called eosinophils which are produced by the body in response to allergen exposure.

Timeline

Start: 2008-06-01
Primary completion: 2013-03-01
Completion: 2013-03-01

Outcome

Met primary endpoint

registry analysis (other test); Mepolizumab; p <0.0001; t-test, 2 sided; NCT00802438 ↗

paper CONCLUSIONS: Mepolizumab reduced airway eosinophil numbers but had a limited effect on airway eosinophil activation markers PMID 28862877 ↗

Publications

Kelly EA, Esnault S, Liu LY, Evans MD, Johansson MW, Mathur S, Mosher DF, Denlinger LC, Jarjour NN. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma. Am J Respir Crit Care Med. 2017 Dec 1;196(11):1385-1395. doi: 10.1164/rccm.201611-2234OC.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mepolizumab	Monoclonal antibody	750 mg	Intravenous